Home/Filings/4/0000899243-21-040245
4//SEC Filing

Stampacchia Otello 4

Accession 0000899243-21-040245

CIK 0001745020other

Filed

Oct 13, 8:00 PM ET

Accepted

Oct 14, 4:40 PM ET

Size

15.4 KB

Accession

0000899243-21-040245

Insider Transaction Report

Form 4
Period: 2021-10-12
Nessi Claudio
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-10-12$16.00/sh+187,500$3,000,000711,479 total
  • Conversion

    Series B Preferred Stock

    2021-10-12693,1520 total
    Common Stock (523,979 underlying)
  • Conversion

    Common Stock

    2021-10-12+523,979523,979 total
Transactions
  • Conversion

    Common Stock

    2021-10-12+523,979523,979 total
  • Purchase

    Common Stock

    2021-10-12$16.00/sh+187,500$3,000,000711,479 total
  • Conversion

    Series B Preferred Stock

    2021-10-12693,1520 total
    Common Stock (523,979 underlying)
Transactions
  • Purchase

    Common Stock

    2021-10-12$16.00/sh+187,500$3,000,000711,479 total
  • Conversion

    Series B Preferred Stock

    2021-10-12693,1520 total
    Common Stock (523,979 underlying)
  • Conversion

    Common Stock

    2021-10-12+523,979523,979 total
Transactions
  • Purchase

    Common Stock

    2021-10-12$16.00/sh+187,500$3,000,000711,479 total
  • Conversion

    Common Stock

    2021-10-12+523,979523,979 total
  • Conversion

    Series B Preferred Stock

    2021-10-12693,1520 total
    Common Stock (523,979 underlying)
Transactions
  • Purchase

    Common Stock

    2021-10-12$16.00/sh+187,500$3,000,000711,479 total
  • Conversion

    Common Stock

    2021-10-12+523,979523,979 total
  • Conversion

    Series B Preferred Stock

    2021-10-12693,1520 total
    Common Stock (523,979 underlying)
Footnotes (3)
  • [F1]Omega Fund VI, L.P. ("Omega VI") held 693,152 shares of the Issuer's Series B Preferred Stock. On October 12, 2021, the Series B Preferred Stock automatically converted into 523,979 shares of the Issuer's Common Stock on a 1-for-1.32286 reverse split basis, immediately prior to and in connection with the closing of a public offering of the Issuer's securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") and without payment of further consideration.
  • [F2]The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.
  • [F3]As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock.

Issuer

Theseus Pharmaceuticals, Inc.

CIK 0001745020

Entity typeother

Related Parties

1
  • filerCIK 0001361712

Filing Metadata

Form type
4
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 4:40 PM ET
Size
15.4 KB